<DOC>
	<DOCNO>NCT01123785</DOCNO>
	<brief_summary>The purpose study evaluate tolerable , safe , effective give INO-8875 eye drop adult glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Dose-Escalation Study Designed Evaluate Tolerability , Safety , Pharmacokinetics ( PK ) , Efficacy Chronic Topical Ocular Application INO-8875 Adults With Ocular Hypertension Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1 . Subject diagnosis ocular hypertension ( OHT ) primary openangle glaucoma ( POAG ) . 2 . Aged 18 75 year . 3 . Mean intraocular pressure ( IOP ) ≥24 ≤34 mm Hg . 1 . No significant visual field loss new field loss within past year . 2 . Cuptodisc ratio ≥0.8 3 . Central corneal thickness &lt; 500 µm &gt; 600 µm 4 . History adult asthma chronic obstructive pulmonary disease 5 . A recent ( acute ) chronic medical condition might obfuscate Subject 's study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>adenosine agonist</keyword>
	<keyword>eye drop</keyword>
	<keyword>primary open angle glaucoma</keyword>
</DOC>